Prevalence of Cardioprotective Medication Use in Coronary Heart Disease Patients in South America: Systematic review and Meta-Analysis

• Published in: Global heart Vol. 17; no. 1; p. 37
• Main Authors: Marzà-Florensa, A, Drotos, E, Gulayin, P, Grobbee, D E, Irazola, V, Klipstein-Grobusch, K, Vaartjes, I
• Format: Journal Article
• Language: English
• Published: England Ubiquity Press 08-06-2022
• Subjects: Angiotensin Receptor Antagonists - therapeutic use; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Coronary Disease - drug therapy; Coronary Disease - epidemiology; Coronary Disease - prevention & control; coronary heart disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; meta-analysis; Prevalence; Review; secondary prevention; south america; time-trends
• ISSN: 2211-8160; 2211-8179; 2211-8179
• DOI: 10.5334/gh.1124

Coronary heart disease (CHD) is the most common cause of death globally, and clinical guidelines recommend cardioprotective medications for patients with established CHD. Suboptimal use of these medications has been reported, but information from South America is scarce.
We conducted a systematic review on prevalence of secondary prevention medication in South America. We pooled prevalence estimates, analysed time-trends and guideline compliance, and identified factors associated with medication use with meta-regression models.
73 publications were included. Medication prevalence varied by class: beta-blockers 73.4%(95%CI 66.8%-79.1%), ACEI/ARBs 55.8%(95%CI 49.7%-61.8), antiplatelets 84.6%(95%CI 79.6%-88.5%), aspirin 85.1%(95%CI 79.7%-89.3%) and statins 78.9%(95%CI 71.2%-84.9%). The use of beta-blockers, ACEI/ARBs and statins increased since 1993. Ten publications reported low medication use and nine reported adequate use. Medication use was lower in community, public and rehabilitation settings compared to tertiary centres.
Cardioprotective medication use has increased, but could be further improved particularly in community settings.